Overview
- The company’s Q3 2025 update showed roughly 20% year-over-year procedure growth and 427 da Vinci systems placed, prompting a guidance raise.
- Shares have climbed nearly 40% from October 2025 lows to roughly $565–$600, placing the market value near $200 billion.
- The installed base reached 10,763 da Vinci systems at the end of Q3 2025, up 13% year over year, with procedure growth outpacing placements and driving higher recurring revenue from instruments and accessories.
- Yahoo Finance reports new FDA clearances for da Vinci use in inguinal hernia repair, cholecystectomy, and appendectomy, broadening eligible procedures.
- Financials remain robust with multi-year double-digit revenue growth, strong margins, and about $4.9 billion in cash and no debt, though high-multiple risks include competition and potential pressure on hospital capital spending.